Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Omalizumab is effective and safe in chronic inducible urticaria (CIndU): Real-world data from a large multi-national UCARE study.
Soegiharto R, Alizadeh Aghdam M, Sørensen JA, van Lindonk E, Bulut Demir F, Mohammad Porras N, Matsuo Y, Kiefer L, Knulst AC, Maurer M, Ritchie C, Rudenko M, Kocatürk E, Criado RFJ, Gregoriou S, Bobylev T, Kleinheinz A, Takahagi S, Hide M, Giménez-Arnau AM, Salman A, Kara RO, Dikicier BS, van Doorn MBA, Thomsen SF, van den Reek JMPA, Röckmann H. Soegiharto R, et al. Among authors: van den reek jmpa. Allergy. 2024 Oct 8. doi: 10.1111/all.16334. Online ahead of print. Allergy. 2024. PMID: 39377745
Frailty and functional dependency in a multicenter cohort of older adults with psoriasis: Prevalence and extent of and implications for psoriasis management.
Ter Haar ELM, van den Reek JMPA, Sadat Chenarani Moghadam M, Schoon Y, Kleinpenning MM, de Jong EMGJ, Lubeek SFK. Ter Haar ELM, et al. Among authors: van den reek jmpa. J Am Acad Dermatol. 2024 Sep 6:S0190-9622(24)02769-5. doi: 10.1016/j.jaad.2024.07.1527. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 39245362 Free article. No abstract available.
Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation.
Soegiharto R, Alizadeh Aghdam M, Sørensen JA, van Lindonk E, Bulut Demir F, Porras NM, Matsuo Y, Kiefer L, Knulst AC, Maurer M, Ritchie C, Rudenko M, Kocatürk E, Criado RFJ, Gregoriou S, Bobylev T, Kleinheinz A, Takahagi S, Hide M, Giménez-Arnau AM, Salman A, Kara RO, Sevimli Dikicier B, van Doorn MBA, Thomsen SF, van den Reek JMPA, Röckmann H. Soegiharto R, et al. Among authors: van den reek jmpa. JAMA Dermatol. 2024 Sep 1;160(9):927-935. doi: 10.1001/jamadermatol.2024.2056. JAMA Dermatol. 2024. PMID: 39018068
Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment.
Thomas SE, Seyger MMB, Mangnus JE, Otero ME, Gostynski AH, Njoo MD, Ossenkoppele PM, Haeck IM, Hendricksen-Roelofzen JHJ, Körver JEM, Dodemont SRP, Tupker RA, Berends MAM, Weppner-Parren LMJT, Keijsers RRMC, Oostveen AM, Peters B, Mommers R, van Doorn MBA, Tjioe M, Veldkamp WR, Kuijpers ALA, Kleinpenning MM, de Jong EMGJ, van den Reek JMPA. Thomas SE, et al. Among authors: van den reek jmpa. Am J Clin Dermatol. 2024 Jul;25(4):685-688. doi: 10.1007/s40257-024-00868-x. Epub 2024 May 27. Am J Clin Dermatol. 2024. PMID: 38802618 No abstract available.
92 results